Knight Therapeutics (TSE:GUD) Sets New 52-Week High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high during trading on Monday . The company traded as high as C$9.98 and last traded at C$9.98, with a volume of 21477 shares. The stock had previously closed at C$9.91.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 price target on shares of Knight Therapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Knight Therapeutics has an average rating of “Buy” and a consensus price target of C$9.50.

Knight Therapeutics Trading Up 0.6%

The company has a market capitalization of C$978.84 million, a PE ratio of 166.17, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.21. The company has a debt-to-equity ratio of 8.86, a current ratio of 2.32 and a quick ratio of 1.79. The company’s fifty day moving average is C$8.66 and its 200-day moving average is C$7.20.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The business had revenue of C$147.59 million for the quarter. On average, analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.